Profese online 2017, 10(2):1-9 | DOI: 10.5507/pol.2017.006

New anticoagulants

Anna Zatloukalová1,2, Jana Janoutová3, Miroslav Homza4, Vladimír Janout3
1 Ústav epidemiologie a ochrany veřejného zdraví, Lékařská fakulta, Ostravská univerzita, Ostrava, Česká republika
2 Centrum epidemiologického výzkumu, Lékařská fakulta, Ostravská univerzita, Ostrava, Česká republika
3 Centrum vědy a výzkumu, Fakulta zdravotnických věd, Univerzita Palackého, Olomouc, Česká republika
4 Kardiovaskulární oddělení, Fakultní nemocnice Ostrava, Česká republika

Background: Until recently, warfarin was the only peroral anticoagulant. Due to its numerous side effects, especially of various types of bleeding, a new oral anticoagulant with the same or better safety was developed. Patients using the new anticoagulant may be able to target all medical and non-medical specializations and at all stages of health care. Therefore, it is appropriate to know at least the basic information on this issue offered by this text.

Aim: The aim of this article is therefore to briefly introduce new oral antikoagulants to health professionals at all levels of education and across disciplines.

Methods: The article summarizes findings from clinical trials. The data has been drawn from current publications. Data was also drawn from the database in particular from the PubMed database, the web resources of the State Drug Control Authority and specific summary of products charakteristics for individual preparations. Further Czech and foreign databases, manuals and results of clinical trials were used.

Results: Large clinical studies have shown that all of these new oral anticoagulants have proven to be as effective or more effective in preventing cerebral stroke and systemic emboli as compared to warfarin. It also proved to be relatively safe or even safer compared to warfarin in terms of the risk of serious bleeding complications. A big step forward was the approval of idarubizumab as a specific antidote for dabigatran. Other anticoagulants still lack specific antidotes.

Conclusion: This drug group should be monitored over the longer term to better characterize its effects, side effects, develop other specific antidotes, and optimize their monitoring during treatment. It is necessary to continue to continue educating in this area.

Keywords: NOAC, new oral anticoagulants, dabigatran, rivaroxaban, apixaban, edoxaban, idarucizumab

Received: June 2017; Accepted: October 2017; Published: November 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zatloukalová, A., Janoutová, J., Homza, M., & Janout, V. (2017). New anticoagulants. Profese Online, 10(2), 1-9. doi: 10.5507/pol.2017.006
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article
    Czech version

    References

    1. Pohlídalová A, Janoutová J, Homza M, Janout V. Nová antikoagulancia. Praktický lékař. 2016;96(3):114-121.
    2. Conolly SJ, Eikelboom J, Joyner C. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-817. Go to original source... Go to PubMed...
    3. Patel MR, Mahaffey KW, Garg J. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-891. Go to original source... Go to PubMed...
    4. Granger CHB, Alexander JH, McMurray JV, et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992. Go to original source... Go to PubMed...
    5. Táborský M. Fibrilace síní: novinky v léčbě 2013. Praha: Axonite CZ; 2013.
    6. Kvasnička J, Penka M, Kvasnička T, a kol. Doporučení české společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) - dabigatran mexilátem, apixabanem a rivaroxabanem. Vnitřní lékařství. 2015;61(6):537-546. Go to PubMed...
    7. Souhrn údajů o přípravku ELIQUIS. The European medicines agency: Science medicines health [online]. EU: An agency of the European Union, 2015 [cit. 2017-05-31]. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
    8. Souhrn údajů o přípravku PRADAXA. The European medicines agency: Science medicines health [online]. EU: An agency of the European Union, 2015 [cit. 2017-05-31]. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
    9. Souhrn údajů o přípravku XARELTO. The European medicines agency: Science medicines health [online]. EU: An agency of the European Union, 2015 [cit. 2017-05-31]. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
    10. Čihák R, Heinc P, Haman L, a kol. Fibrilace síní: Doporučený diagnostický a léčebný postup České kardiologické společnosti vypracovaný Pracovní skupinou arytmie. Vnitřní lékařství. 2012;58(Suppl 1):41-69.
    11. Michalcová J, Penka M, Buliková A, Zavřelová J, Štěpařová A. Nová - přímá perorální antikoagulancia: aktuální přehled. Vnitřní lékařství. 2016;62(10):805-813. Go to PubMed...
    12. Becker RC. The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. J Thromb Thrombolysis 2016;41(2):273-278. Go to original source... Go to PubMed...
    13. Mo Y, Yam FK. Recent Advances in the Development of Specific Antidotes for Target-Specific Oral Anticoagulants. Pharmacotherapy. 2015;35(2):198-207. Dostupné z DOI: <http://dx.doi.org/10.1002/phar.1532>. Go to original source... Go to PubMed...
    14. Kvasnička J, Malíková I. Nová perorální přímá antikoagulancia (NOAC) - jak řešit možné problémy s vyšetřením koagulace. Anest. intenziv. Med. 2014;25(5):367-372.
    15. Václavík J, Dabigatran antidote idarucizumab has come to clinical practice, Cor et Vasa 58 (2016) e1-e3. Available from: http://www.sciencedirect.com/science/article/pii/S0010865016000175 Go to original source...
    16. Doporučení České společnosti pro trombózu a hemostázu 2015: Postup při krvácení a perioperační management u nemocných léčených novými perorálními antikoagulancii (NOACs): dabigatran-etexilát (PRADAXA™), rivaroxaban (XARELTO™) a apixaban (ELIQUIS™). Available from: http://www.csth.cz/soubory/csth-postup-pri-krvaceni.pdf
    17. Kábrová R, Kábr K. Edoxaban - farmakologický profil. Kardiol Rev Int Med. 2017;19(1):45-50.
    18. Souhrn údajů o přípravku LIXIANA. The European medicines agency: Science medicines health [online]. EU: An agency of the European Union, 2016 [cit. 2017-05-31]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf
    19. Giugliano, RP, CHT. Ruff, E Braunwald, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 2013;369(22):2093-2104. DOI: 10.1056/NEJMoa1310907. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1310907 Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content